BioCentury
ARTICLE | Company News

BioXell, Lay Line, Roche deal

February 22, 2010 8:00 AM UTC

BioXell terminated its 2006 deal with Lay Line Genomics for exclusive rights to Lay Line's BXL1H5 (formerly MNAC13) technology. BioXell will return all rights to Lay Line for the humanized antibody against TrkA ( NTRK1; neurotrophic tyrosine kinase receptor 1), which is in preclinical testing for chronic pain. BioXell also said it plans to terminate its license with Roche for its Vitamin D3 technology and assets. BioXell was spun out from Roche in 2002 with over 100 vitamin D analogs and IP (see BioCentury, April 1, 2002 & Feb. 20, 2006). ...